Table 2 Reported adverse events in the double-blinded, placebo-controlled trials only.
From: Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation
Adverse event | Frequency (%) Atosiban | Frequency (%) Betamimetics | Relative risk and Confidence Intervals | p-value |
|---|---|---|---|---|
Tachycardia | 5.50% | 75.50% | RR = 0.07, 95% CI = 0.05, 0.11 | <0.001 |
Palpitation | 2.20% | 15.60% | RR = 0.15, 95% CI = 0.07, 0.3 | <0.001 |
Vomiting | 6.90% | 21.80% | RR = 0.31, 95% CI = 0.21, 0.48 | <0.001 |
Headache | 9.70% | 18.60% | RR = 0.52, 95% CI = 0.35, 0.76 | <0.001 |
Hyperglycaemia | 6.40% | 12.40% | RR = 0.53, 95% CI = 0.38, 0.85 | 0.008 |
Tremor | 1.40% | 15.90% | RR = 0.09, 95% CI = 0.04, 0.22 | <0.001 |
Nausea | 11.90% | 15.90% | RR = 0.75, 95% CI = 0.52, 1.08 | 0.121 |
Dyspnoea | 0.30% | 7.30% | RR = 0.07, 95% CI = 0.02, 0.3 | <0.001 |
Chest pain | 1.10% | 4.80% | RR = 0.22, 95% CI = 0.08, 0.65 | 0.006 |
Hypokalemia | 0.80% | 6.50% | RR = 0.15, 95% CI = 0.05, 0.45 | <0.001 |
Hypotension | 3.30% | 5.70% | RR = 0.59, 95% CI = 0.29, 1.16 | 0.127 |
Anxiety | 1.10% | 2.40% | RR = 0.46, 95% CI = 0.15, 1.48 | 0.195 |
Syncope | 0.60% | 0.50% | RR = 1.02, 95% CI = 0.17, 5.98 | 0.984 |
Pulmonary oedema | 0.30% | 0.50% | RR = 0.6, 95% CI = 0.08, 4.45 | 0.614 |
Myocardial ischemia | 0.00% | 0.30% | RR = 0.34, 95% CI = 0.01, 8.3 | 0.509 |
Foetal tachycardia | 3.30% | 27.70% | RR = 0.13, 95% CI = 0.07, 0.26 | <0.001 |